STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...

Celltrion will cancel treasury shares worth 203.3 billion won ($140 million) to enhance shareholder value, the Korean drugmaker said on Friday. The shares set for cancellation are its entire ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Tuesday it aims to achieve 5 trillion won (US$3.46 billion) in sales this year, helped by an expanded biosimilar lineup. The annual ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount to the reference product. Steqeyma is available in both subcutaneous ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to the Costco Member ...

Celltrion developed and manufactured the world’s first monoclonal antibody biosimilar, followed by the first and only subcutaneous (SC) formulation infliximab, ‘Remsima ® SC’, which was ...